PA-BENTLEY-SYSTEMS
9.6.2020 20:34:08 CEST | Business Wire | Press release
Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure today announced that its annual infrastructure event, the Year in Infrastructure 2020 Conference, is “going digital.” This new digital format will bring together, now for a broader global community, the thought leadership, networking, and learning content that Bentley conference attendees have come to expect.
The virtual Year in Infrastructure 2020 Conference provides complementary access to a wide range of content relevant to infrastructure professionals in every role and at every phase of the infrastructure lifecycle. Highlights include:
Live Judging: Year in Infrastructure 2020
Awards Finalists’ Presentations – October 5 - 16
The Year in Infrastructure
Awards finalists, chosen by independent juries of industry experts, present their projects to the judges beginning October 5. This is your chance to hear from the people behind the most extraordinary infrastructure projects of the year as they tell the story of how they leveraged digital advancements to achieve unprecedented outcomes.
Year in Infrastructure
2020
Executive Perspectives – October 20 - 21
Greg Bentley, CEO of Bentley Systems, will be joined by leading infrastructure executives for an interactive discussion on the resilience challenges they face and how to meet those challenges through digital advancement.
Keith Bentley, founder and chief technology officer, will discuss Bentley’s open strategy for digital twins. Keith will be joined by other leading industry visionaries who have deployed digital twins successfully for project delivery or asset performance.
TwinTalks
Premiere – October 20
Infrastructure digital twins will be front and center at this year’s event. Join leading industry figures as they moderate six sector-specific TwinTalks
, exploring the implications of digital twins for Digital Cities, Design and Construction, Digital Plants, Energy Utilities, Rail and Transit, and Roads and Bridges. Listen to interactive panel discussions with leading industry and business leaders and discover the fascinating opportunities that digital twins introduce for each of these critical infrastructure sectors. The initial October 20 TwinTalks are each part of a three-part series, with the second and third installments of the TwinTalks’ series scheduled through mid-November.
Year in Infrastructure 2020
Awards Ceremony – October 21
After months of jury deliberations, the winners of the Year in Infrastructure 2020
Awards
will be announced in our live global broadcast. Don’t miss what has been called the “Academy Awards of Infrastructure.”
ACCELERATE Sessions – October 27 and beyond
Join Bentley product executives Dustin Parkman (Project Delivery), Robert Mankowski (Digital Cities), Ken Adamson (Design Integration), and Alan Kiraly (Asset and Network Performance) as they and their leadership teams review the latest advancements in Bentley applications and cloud services. These sessions will kick-off a multi-track program of more than 100 ACCELERATE sessions that will continue into November. ACCELERATE will feature Bentley and user experts in panel discussions and interactive demonstrations on the latest product advances, innovations, and best practice digital workflows.
Learn More about the Year in Infrastructure 2020
Conference
Join us online for the virtual Year in Infrastructure 2020
Conference
and learn from peers, industry experts, and innovators who will share their infrastructure digital twins’ successes. Register for updates at https://yii.bentley.com/en
.
Image: Year in Infrastructure 2020 Conference
Caption: The Year in Infrastructure 2020 Conference is Going Digital.
About Bentley Systems
Bentley Systems is a leading global provider of software solutions to engineers, architects, geospatial professionals, constructors, and owner-operators for the design, construction, and operations of infrastructure. Bentley’s MicroStation
-based engineering and BIM applications, and its digital twin cloud services, advance the project delivery (ProjectWise
) and the asset performance (AssetWise
) of transportation and other public works, utilities, industrial and resources plants, and commercial and institutional facilities.
Bentley Systems employs more than 3,500 colleagues and generates annual revenues of more than $700 million in 172 countries. From inception in 1984, the company has remained majority-owned by its five founding Bentley brothers. www.bentley.com
Bentley, the Bentley logo, AssetWise, MicroStation, and ProjectWise are either registered or unregistered trademarks or service marks of Bentley Systems, Incorporated or one of its direct or indirect wholly owned subsidiaries. All other brands and product names are trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005748/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom